Replies to post #149274 on Cytodyn Inc (CYDY)

[jimmy667]

CytoDyn is one of only 3 allowed to finish the trials. I believe also the only one to allowed to finish without modifications. Absolutely the only one to have been granted open-label extension where all placebo patients were then given the Leronlimab.
It is a near-lock for some type of EUA.
CytoDyn end game might result in multiday gap-up runs that might dwarf the June 2020 runs. Breakaway gap and run. Not the usual one gap and fade. No way out. CYDY might gap up way past any reasonable buy/stops with no long call options available to hedge this extreme risk. The only way I can see to hold short CYDY and mitigate risk would be to have 3x or 4x long positions in Humanagen and Relief that should get a sympathetic sharp share price rise when CytoDyn explodes upwards.

[Maverick0408]

Interesting news pieces about big pharmas, and the role of some of the media companies in such activities:

https://www.classaction.com/news/stat-news-credibility-problem/

https://www.healthnewsreview.org/2017/09/a-blow-to-stats-credibility-public-relations-firm-may-have-ghostwritten-op-ed-praising-drug-reps/